Investors bring class action against Mayne Pharma (ASX:MYX)
Mayne Pharma (MYX) faces a class action over alleged failures to inform…
Mayne Pharma Group Limited (ASX:MYX)
26.5¢
-0.005 (-1.85%)
MCAP $476.5M
Last trade
16.10pm 24/01/2022
20mins delayed
Latest Announcements
17/01/2022MYXMayne Pharma Group Limited
12/01/2022MYXMayne Pharma Group Limited
07/12/2021MYXMayne Pharma Group Limited
14,947
MCap
03/12/2021MYXMayne Pharma Group Limited
30/11/2021MYXMayne Pharma Group Limited
29/11/2021MYXMayne Pharma Group Limited
23/11/2021MYXMayne Pharma Group Limited
5,216
MCap
23/11/2021 Price SensitivePSMYXMayne Pharma Group Limited
8,010
MCap
Company Overview
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
